This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Renal Cell Carcinoma
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Provided treatments

  • Drug: Atezolizumab
  • Other: Placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03024996. The sponsor of the trial is Hoffmann-La Roche and it is looking for 778 volunteers for the current phase.
Official trial title:
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy